Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors
| العنوان: | Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors |
|---|---|
| المؤلفون: | Daniel Putzer, Reto Bale, Edward W. Johnston, Gregor Laimer, Gernot Eberle, Peter Schullian |
| المصدر: | Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020) Scientific Reports |
| بيانات النشر: | Nature Publishing Group, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Radiofrequency ablation, Pleural effusion, lcsh:Medicine, Single Center, Disease-Free Survival, Article, 030218 nuclear medicine & medical imaging, law.invention, Cholangiocarcinoma, Stereotaxic Techniques, 03 medical and health sciences, 0302 clinical medicine, law, Carcinoma, Medicine, Humans, lcsh:Science, Survival rate, Aged, Retrospective Studies, Aged, 80 and over, Radiofrequency Ablation, Multidisciplinary, business.industry, Liver Neoplasms, lcsh:R, Neoplasms, Second Primary, Perioperative, Middle Aged, medicine.disease, Survival Rate, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Surgical oncology, Catheter Ablation, Female, lcsh:Q, Radiology, Neoplasm Recurrence, Local, business, Complication, Liver cancer |
| الوصف: | To assess the safety and clinical outcomes of multi-probe stereotactic radiofrequency ablation (SRFA) for very large (≥8 cm) primary and metastatic liver tumors with curative treatment intent. A retrospective, single center study carried out between 01.2005 and 06.2018. 34 consecutive patients had a total of 41 primary and metastatic liver tumors with a median size of 9.0 cm (8.0–18.0 cm) at initial SRFA. Patients were treated under CT guidance using a 3D navigation system. Endpoints consisted of (i) technical efficacy; primary - requiring one treatment, and secondary – requiring two treatments (ii) complication and mortality rates (iii) local and distant recurrence (LR), (iv) disease free survival (DFS), (v) overall survival (OS). 33/41 tumors were successfully ablated at initial SRFA (80.5% primary technical efficacy rate (PTE)). Four tumors required repeat ablation, resulting in a secondary technical efficacy (STE) rate of 90.2%. Local tumor recurrence (LR) developed in 4 of 41 tumors (9.8%). The 30-day perioperative mortality was 2.3% (1/ 44 ablations). The total major complication rate was 20.5% (9 of 44 ablations). Three of nine (33.3%) major complications, such as pleural effusion, pneumothoraces or perihepatic hemorrhages were relatively easy to treat. The overall survival (OS) rates at 1-, 3-, and 5- years from the date of the first SRFA were 87.1%, 71.8%, and 62.8% for patients with hepatocellular carcinoma (HCC) and 87.5%, 70.0% and 70.0% for patients with intrahepatic cholangiocarcinoma (ICC) respectively. Patients with metastatic disease had OS rates of 77.8% and 22.2% at 1- and 3- years. The clinical results of SRFA in this study are encouraging and warrant a prospective multicenter study. SRFA may become one of the best therapeutic choices for a growing number of patients with primary and metastatic liver cancer. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b846580a134c1723d114593d1b8133d7Test http://link.springer.com/article/10.1038/s41598-020-58383-yTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b846580a134c1723d114593d1b8133d7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|